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Background/aim: It is not always easy to diagnose pulmonary neuroendocrine tumors (PNETs). The aim of the present study is to make
a differential diagnosis by studying the same markers in patients with non-small-cell lung carcinoma (NSCLC), patients with benign
lung disease (chronic obstructive pulmonary disease and pneumonia), and healthy volunteers to determine the roles of these markers
in pulmonary neuroendocrine tumor diagnosis and to identify their power.
Materials and methods: A total of 100 participants including 23 PNET patients and 28 NSCLC patients who were pathologically diagnosed but not yet treated, 25 participants with benign disease, and 24 healthy volunteers were included in this cross-sectional study.
Results: No significant difference was found between the chromogranin A (CgA) and squamous cell carcinoma antigen 1 (SCCA1)
values among the groups (PNET, NSCLC, benign, healthy volunteers), but the difference in progesterone-releasing peptide (ProGRP),
neuron-specific enolase (NSE), and adjusted NSE was statistically significant (P values were respectively ProGRP, P = 0.006; NSE, P =
0.015; NSE adjusted, P = 0.09). In a comparison of the PNET and NSCLC groups, having a ProGRP value higher than 84.6 pg/mL revealed PNET with 60.9% sensitivity and 89.3% specificity (P = 0.001).
Conclusion: The ProGRP value is the only indicator that distinguishes the PNET group from the other 3 groups.
Key words: Neuroendocrine tumor, lung neoplasm, markers, carcinoid

1. Introduction
Pulmonary neuroendocrine tumors (PNETs) constitute
approximately 20% of lung cancers [1–3]. According to
the European Neuroendocrine Tumor Society expert
consensus report, neuroendocrine tumors are classified
as typical carcinoid (TC), atypical carcinoid (AC), smallcell lung cancer (SCLC), and large cell neuroendocrine
tumor (LCNT) [4]. Approximately 90% of tumors with
endobronchial involvement are symptomatic and may
present with hemoptysis, cough, recurrent pulmonary
infections, and unilateral wheezing. However, 1/2 to 1/5 of
PNET patients are asymptomatic [5–8]. The diagnosis of
these patients is often coincidental with the detection of a
lesion via an imaging method applied for another reason.

However, with small biopsy specimens, carcinoid tumors
may be mistakenly diagnosed as SCLC, whereas LCNT may
be misdiagnosed as poorly differentiated adenocarcinoma,
squamous cell carcinoma, or basaloid carcinoma. In this
context, the question is whether the diagnosis of PNET
patients can be supported by using some additional tests.
For this purpose, attempts have been made to develop
various immunohistochemical and biochemical markers.
The most commonly used immunohistochemical
markers for neuroendocrine tumors are chromogranin,
CD56, synaptophysin, and Ki-67 [8]. Progastrin-releasing
peptide (ProGRP), used as a biochemical marker, is the
precursor of GRP and is used as a tumor marker instead
of nonstable GRP because its half-life is very short.
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ProGRP is a more frequently studied marker in SCLC; the
sensitivities are in the range of 47%–86% and the specificity
is over 90% when the threshold value is from 33.8 to 53 pg/
mL [9–14]. Even if the result is >100 pg/mL, it has been
emphasized that a neuroendocrine origin or small-cell
component must be searched for even if the pathological
diagnosis is NSCLC [15]. Neuron-specific enolase (NSE) is
the neuroendocrine-specific isoenzyme of enolase. It plays
a role in aerobic glycolysis and is found in many neural
and neuroendocrine tumors [16]. Its sensitivity is 20%–
81% in SCLC; when found positive, a better prognosis is
suspected [16,17]. It has also been shown to be elevated in
atypical carcinoids along with SCLC [18]. Chromogranins
are acidic secretory proteins released from neuronal or
neuroendocrine cells [16]. They were found to be high in
75% of 20 cases of pulmonary carcinoid tumors in which
plasma chromogranin A (CgA) levels were studied [19].
In a study examining the CgA and NSE levels in SCLC,
chromogranin sensitivity was found to be higher (61% and
57%, respectively) [20]. Squamous cell carcinoma antigen
1 (SCCA1) was originally demonstrated in squamous cell
carcinoma of the cervix; elevated serum levels suggest lung
squamous cell carcinoma when evaluated with masses in
the lungs. Taking a threshold value of 1.5 ng/mL, only
7.5% of patients with SCLC were found to be positive [21].
For this reason, negative SCCA1 detection with other
positive serum markers, especially in neuroendocrine lung
cancer, increases the likelihood of diagnosis. The authors
noted that sensitivity was 79.5% and specificity was 99.6%
for SCLC in the use of SCCA1 (when used as an exclusion
criterion) in combination with NSE and ProGRP [16,22].
Although these are the current available data, as of yet no
prospective studies have evaluated these 4 tests in PNET
cases.
The primary aim of this study is to determine the
sensitivity, specificity, negative predictive value, and
positive predictive value of ProGRP, NSE, CgA, and
SCCA1 obtained from peripheral venous blood samples
in pathologically diagnosed PNET cases. In order to
determine the role of these markers in PNET diagnosis
and their power in the differential diagnosis, we aimed
to make the differential diagnosis by studying the same
markers in patients with NSCLC, patients with benign
lung disease (chronic obstructive pulmonary disease and
pneumonia), and healthy volunteers.
2. Materials and methods
2.1. Patient and control groups
The project was approved by the ethics committee of
Erciyes University on 26.09.2014 with number 2014/528.
Enrollment of participants in the project began on 15 June
2015; within 20 months of this date, all participants were
enrolled in the study.

Patients who were diagnosed with PNET (TC, AC,
LCNT, SCLC) or NSCLC between the ages of 18 and 80 and
had not received any treatment (surgery, chemotherapy,
or radiotherapy) were included in the study. Those with
benign pulmonary disease (chronic obstructive pulmonary
disease [COPD], pneumonia) and healthy volunteers were
also included. Active hepatic disease (active hepatitis B,
active hepatitis C, and cirrhosis), a glomerular filtration
rate of <30 mL/min, and regular proton pump inhibitor
intake within the last month were the exclusion criteria for
this study.
A total of 100 participants including 23 PNET and 28
NSCLC patients, 25 participants with benign disease, and
24 healthy volunteers were included in this cross-sectional
study. An informed consent form was obtained from all of
the participants.
2.2. Staging of PNET and NSCLC groups
Routinely used F18-labeled fluorodeoxyglucose (FDG)
positron emission tomography-computed tomography
(PET-CT) was used in the pretreatment staging of PNET
and NSCLC cases. Staging of these cases was performed
according to the 8th staging system [23]. In the PNET
group, cases of SCLC were staged as limited disease or
extensive disease [24].
2.3. Biochemical analysis
ProGRP, NSE, CgA, and SCC/A1 were studied in blood
samples obtained from all patients and healthy control
subjects. Serum/plasma samples obtained from venous
blood samples were stored at –70 °C in the deep-freeze
room of the Erciyes University Medical Faculty’s Chest
Diseases Clinic, and all of the samples were studied when
the target number of participants was obtained.
Serum NSE and ProGRP levels were studied in Erciyes
University’s Central Biochemistry Laboratory with a
Roche Cobas E601 device (Roche Diagnostics GmbH,
Mannheim, Germany) and commercial kit (ProGRP
Catalog No. 06505961190, NSE Catalog No. 12133113
122, Roche Diagnostics GmbH). In order to monitor the
quality of the ProGRP measurements, the control sera
obtained from the manufacturer where the measurement
was made were also measured with the same kit and
device. The 2 measurement values of the ProGRP control
1 serum with a measurement target range of 35.0–60.8 pg/
mL were found to be 43.94 and 44.87 pg/mL, and the 2
measurement values of the ProGRP control 2 serum with
a measurement target range of 507.0–883.0 pg/mL were
found to be 717.4 and 722.7 pg/mL. Since these control
sera were used to measure the desired target range, the
ProGRP assays were deemed to be accurate.
Since hemolysis causes false increments in NSE
values, hemolysis-free NSE values were also calculated in
accordance with the literature and the results were given as
adjusted NSE [25].
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Serum CgA and serum SCCA1 levels were measured
in accordance with the manufacturer’s manual with
commercial ELISA kits numbered MBS704285 and
MBS721625 (MyBioSource, Inc., San Diego, CA, USA),
respectively.
2.4. Statistical methods
SPSS 22.0 (IBM Corp., Armonk, NY, USA) was used
for statistical analysis. The distribution of continuous
variables was tested with the one-sample Kolmogorov–
Smirnov test, and the data are shown as mean ± standard
deviation or median and minimum–maximum intervals.
CgA, ProGRP, NSE, adjusted NSE, and SCCA1 data were
given using medians and 25%–75% ranges. Categorical
variables were reported as frequency and group
percentiles. The receiver operating characteristic (ROC)
curves were obtained by individual analysis of the serum
markers of patients and control groups using the easyROC
[26] and medCalc (1993–2017 MedCalc Software bvba,
Ostend, Belgium) programs and the area under the curve
was calculated. The threshold value was calculated using
the Youden index and the sensitivity, specificity, positive
predictive value, and negative predictive value were found
with the medCalc program according to this value. All
P-values were two-tailed and P < 0.05 was considered
significant. In the power analysis performed before the
study, a value of 0.40 was used considering the high effect
size proposed by Cohen [27]. The number of units for each
variable determined as 90% power and 5% for type 1 error
was 24 for each group and at least 96 in total. The power
for the relevant variables after the study was calculated
as follows with type 1 error of 5%: ProGRP, 96.1%; NSE,
96.6%; CgA, 22.8%; SCCA1, 4.9%; adjusted NSE, 98.4%.
3. Results
A total of 100 participants including 23 PNET patients
(23%) (7 TC, 2 AC, 14 SCLC), 28 NSCLC patients (28%)
(15 adenocarcinoma, 13 squamous cell carcinoma), 25
participants with benign disease (25%) (8 pneumonia, 17
COPD patients), and 24 healthy volunteers (24%) were
included in this study. When the age differences between
the groups were examined, it was found that the difference
was statistically significant; the reason for this significance
was that the average age of healthy participants was lower
than that of the patients in the NSCLC and benign groups
(P < 0.05). While males were dominant in the PNET and
NSCLC groups, females were dominant in the healthy
volunteers (P < 0.05). Demographic findings related to the
patients are shown in Table 1.
When carcinoid tumors (typical and atypical) were
staged, it was found that 3 patients (33.3%) were at stage
1a3 and 2 patients (22.2%) were at 2b. In small-cell lung
cancer patients, 13 patients (92.9%) had extensive disease
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Table 1. Disease groups and demographic data.
n (%)
PNET
Tumor type
Typical carcinoid
Atypical carcinoid
Small cell lung cancer
Smokingπ
Active or ex-smoker
Nonsmoker
Male/female&
Age*
NSCLC
Tumor type
Adenocarcinoma
Squamous cell carcinoma
Smokingπ
Active or ex-smoker
Nonsmoker
Male/female&
Age*
Benign
Subdisease
Pneumonia
COPD
Smokingπ
Active or ex-smoker
Nonsmoker
Female/male&
Age*
Healthy control
Smokingπ
Active or ex-smoker
Nonsmoker
Male/female&
Age*#

23
7 (30.4)
2 (8.7)
14 (60.9)
21 (91.3)
2 (8.7)
19/4
56.9 ± 12.9
28
15 (53.6)
13 (46.4)
24 (85.7)
4 (14.3)
25/3
61.5 ± 10.9
25
8 (32)
17 (68)
18 (72)
7 (28)
12/13
58.9 ± 15.0
24
17 (70.8)
7 (29.2)
7/17
48.5 ± 9.3

*: Given as mean ± standard deviation.
#
: The age differences were statistically significant; the reason
for this significance was the fact that the average age of healthy
participants was lower than that of the patients in the NSCLC
and benign groups (P < 0.05).
&
: The difference was statistically significant (P < 0.05).
π
: The difference was not statistically significant (P > 0.05).

and 1 patient (7.1%) had limited disease. The stages of the
patients are given in Table 2.
There was no significant difference among the 4 groups
(PNET/ NSCLC/benign/healthy volunteers) in terms of
CgA and SCCA1 values, but the difference in the ProGRP,
NSE, and adjusted NSE values was found to be statistically
significant (ProGRP, P = 0.006; NSE, P = 0.015; adjusted
NSE, P = 0.09). Table 3 gives the numerical values of these
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Table 2. Staging of malignant cases.
n (%)
PNET (n = 23)
Carcinoid tumors (n = 9)
1a2
1a3
1b
2a
2b
4a
Small cell lung cancer (n = 14)
Limited stage disease
Extensive stage disease
NSCLC (n = 28)
1a2
1a3
1b
2b
3a
3b
3c
4a
4b

1 (11.1)
3 (33.3)
1 (11.1)
1 (11.1)
2 (22.2)
1 (11.1)
1 (7.1)
13 (92.9)
1 (3.6)
1 (3.6)
1 (3.6)
1 (3.6)
2 (7.1)
5 (17.9)
2 (7.1)
8 (28.6)
7 (25)

parameters in detail. In addition, the box-plot curves of
these values are given in Figure 1.
The reason for the significance of ProGRP among the
4 groups was the significant difference among all groups
compared to PNET (PNET–NSCLC, PNET–benign,
and PNET–healthy, P = 0.042, P = 0.002, and P = 0.002,
respectively). The difference in these 4 groups of NSE
was due to the significant difference between the PNET–
healthy, NSCLC–benign, and benign–healthy groups

(P = 0.005, P = 0.005, P = 0.03, respectively). When the
adjusted NSE values were examined, it was determined
that the significant differences between the PNET–healthy,
PNET–benign, and NSCLC–healthy groups affected the
total analysis (P = 0.003, P = 0.023, P = 0.018, respectively).
A comparison of PNET and other groups with ROC
analysis in terms of CgA, ProGRP, NSE, adjusted NSE,
and SCCA1 is given in Table 4. It was found that NSE and
adjusted NSE values higher than 40.9 ng/mL and 12.9 ng/
mL, respectively, for both groups revealed PNET with
47.8% and 60.9% sensitivity and 87.5% and 87% specificity,
respectively (P < 0.05). When multiple ROC analyses were
conducted on the ProGRP, NSE, and adjusted NSE values,
which were significant in the comparison of the PNET and
healthy groups, no parametric superiority to another was
detected (P > 0.05) (Figure 2). In the comparison of the
PNET and NSCLC groups, it was found that a ProGRP
value higher than 84.6 ng/mL revealed PNET with 60.9%
sensitivity and 89.3% specificity (P = 0.001).
The hypothesis that SCCA1 squamous cell lung
cancer can be used to differentiate the other NSCLC and
PNET groups was also studied. However, no significant
differences were found in distinguishing squamous cell
lung cancer patients from other adenocarcinoma patients
or distinguishing them from PNET patients (in the PNET
group, 27.8 pg/mL (19.6–46.1); in adenocarcinoma
patients, 32.1 pg/mL (16.3–43.8); in squamous cell
carcinoma cases, 33.8 pg/mL (21.6–44.3); values are given
as the median value (25%–75%, P > 0.05)). However,
ROC analysis for SCCA1 values between the PNET and
squamous cell carcinoma and the squamous cell carcinoma
and adenocarcinoma groups did not yield a significant
result (P > 0.05).

Table 3. Progastrin-releasing peptide (ProGRP), neuron-specific enolase (NSE), NSE adjusted, chromogranin A (CgA), and squamous
cell carcinoma antigen 1 (SCCA1) values in the pulmonary neuroendocrine tumors (PNET), non-small-cell lung carcinoma (NSCLC),
benign, and healthy groups.
PNET (n = 23)

NSCLC (n = 28)

Benign (n = 25)

Healthy (n = 24)

P

CgA (ng/mL)

1644.5 (946.9–1644.5) 1363.4 (1068.1–1916.0) 1554.4 (1034.7–1900.8) 1675.8 (1419.2–2786.5) >0.05

ProGRP (pg/mL)

151.8 (39.8–2563.0)

56.8 (37.9–78.5)

45.9 (34.5–59.)

47.9 (32.9–62.6)

0.006*

NSE (ng/mL)

29.0 (12.0–147.4)

24.3 (15.8–52.8)

22.0 (15.5–33.0)

13.2 (11.9–22.5)

0.015#

NSE adjusted (ng/mL)

17.1 (9.6–135.1)

13.8 (9.9–28.6)

11.3 (7.3–17.8)

9.8 (8.6–11.6)

0.009&

SCCA1 (pg/mL)

27.8 (19.6–46.06)

32.9 (21.6–43.4)

34.5 (16.9–75.3)

36.8 (24.7–58.4)

>0.05

Values are given as median (25%–75%).
*: The difference was due to the high ProGRP levels in patients with PNET.
#
: The difference was due to the high NSE levels in patients with PNET.
&
: The difference was due to the high NSE adjusted levels in patients with PNET.
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Figure 1. Comparison of CgA (chromogranin A, ng/mL), ProGRP (progastrin-releasing peptide, pg/mL), NSE (neuron-specific
enolase, ng/mL), and NSE-adjusted values in patient groups and healthy volunteers.

4. Discussion
In this study, the ProGRP value was found to be the only
marker that distinguished the PNET group from the other
3 groups. The threshold value was found to be 95.2 pg/mL
for the ProGRP value in the comparison of the PNET group
and the healthy group and 87.3 pg/mL in the comparison of
the benign group and the PNET group. In the comparison
of the PNET and NSCLC groups in our study, ProGRP
and adjusted NSE values higher than 84.6 pg/mL revealed
PNET with 60.9% sensitivity and 89.3% specificity. In a
study investigating diagnostic and prognostic criteria in
NSCLC, ProGRP with a specificity of 95% and a sensitivity
of 78.4% was reported [11]. In a similar study conducted
by Molina et al., ProGRP was shown to have a sensitivity
of 60%–70% for detecting limited SCLC and 75%–90%
for detecting extensive SCLC [22]. Another study showed
that the ProGRP level was found to be higher than those
of NSE and chromogranin A in a comparison of SCLC and
NSCLC [9]. These values are similar to those in our study.
In addition, although age and sex were different between
groups in the present study, Korse et al. showed a weak
association of ProGRP with age and no association with
sex in 282 neuroendocrine tumor patients and 297 healthy
volunteers [28].
In this cross-sectional study, both NSE (threshold
value of 40.9 ng/mL) and adjusted NSE (threshold value of
13.9 ng/mL) were significant in distinguishing PNET from
the healthy group, whereas only adjusted NSE (threshold
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value of 25.4 ng/mL) was significant in a comparison of the
PNET and benign groups. In a study in which CYFRA21.1,
carcinoembryonic antigen, SCCA1, and NSE were studied
in SCLC, the sensitivity of NSE was significantly higher
than that of the other markers (sensitivity 81.2%) [22].
However, the sensitivities determined in other studies
ranged from 43% to 52% [16]. In another study, ProGRP
was found to be superior to NSE in distinguishing SCLC
from benign disease and NSCLC [29]. In our study, the
sensitivity of both NSE and adjusted NSE to distinguish
between SCLC and NSCLC was 47.8%, but this difference
was not statistically significant. In addition, although NSE
can provide important information in the diagnosis and
follow-up of SCLC, evaluation of serum NSE levels should
be done with caution. NSE caused by fragmented red
blood cells and thrombocytes in hemolyzed samples may
lead to false positive evaluation [30]. We obtained adjusted
NSE values in our study using a hemolytic index to be
compatible with the study of Verfaillie et al. to avoid this
mistake [25]. However, when the methodologies of studies
performed with lung cancer cases were examined, the use
of adjusted NSE values was not clearly understood.
Several studies tested the utility of CgA in the
diagnosis of SCLC and reported different results. A wide
range of sensitivity values were defined in SCLC, and
this difference was thought to be explained by the use of
different epitopic targets and different body fluids [16]. In
a study using polyclonal anti-CgA antibodies by ELISA,

TUTAR et al. / Turk J Med Sci
Table 4. Comparisons of pulmonary neuroendocrine tumors (PNET) and other
groups with ROC analysis in terms of progastrin-releasing peptide (ProGRP),
neuron-specific enolase (NSE), adjusted NSE, chromogranin A (CgA), and
squamous cell carcinoma antigen 1 (SCCA1) values.
CgA

ProGRP

NSE

NSE adjusted

SCCA1

PNET–Healthy
Threshold value
AUC
P
Sensitivity (%)
Specificity (%)
PPV (%)
NPV (%)

1333.3
0.582
NS
39.1
87.5
75.0
60.0

95.2
0.748
0.001
60.9
100
100
72.7

40.9
0.683
0.027
47.8
95.8
91.7
65.7

12.7
0.728
0.003
60.9
87.5
82.4
70.0

49.3
0.599
NS
37.5
87.0
75.0
57.1

PNET–Benign
Threshold value
AUC
P
Sensitivity (%)
Specificity (%)
PPV (%)
NPV (%)

1564.2
0.519
NS
56.5
60.0
56.5
60.0

87.3
0.734
0.003
60.9
92.0
87.5
71.9

51.1
0.584
NS
47.8
100
100
67.6

25.4
0.689
0.018
47.8
100
100
67.6

59.9
0.546
NS
40.0
91.3
83.3
58.3

PNET–NSCLC
Threshold value
AUC
P
Sensitivity (%)
Specificity (%)
PPV (%)
NPV (%)

1404.9
0.547
NS
60.9
57.1
53.8
64.0

84.6
0.699
0.016
60.9
89.3
82.4
73.5

54.0
0.530
NS
47.8
78.6
64.7
64.7

35.3
0.586
NS
47.8
82.1
68.7
65.7

23.3
0.502
NS
71.4
43.5
60.6
55.6

AUC: Area under the curve; PPV: positive predictive value; NPV: negative
predictive value; NS: not significant.
The ProGRP and SCCA1 threshold values are given in pg/mL, whereas the CgA
and adjusted NSE threshold values are given in ng/mL.

sensitivity was shown to reach 39%, but CgA levels were
found to increase with advanced disease stage, and a large
number of patients in the study were reported to have
advanced disease [31]. In the study of Børglum et al. with
epitopes identified at the N-terminal end of CgA, the
diagnosis was made with 58% sensitivity in SCLC with
limited disease and with 100% sensitivity in extensive
stage disease [32]. The low diagnostic susceptibility rates
of 17%–42% in limited disease and 55%–67% in extensive
disease reported in different trials using different epitopes
demonstrate the effect of appropriate epitope selection on
diagnostic sensitivity [30]. Although SCLC patients were
mostly advanced stage, the CgA levels among the groups
was not statistically significant in our study. This is because
the present study included fewer SCLC patients.
In our study, we hypothesized that SCCA1 could
distinguish squamous cell carcinoma from PNET, but there

was no significant difference among the groups in terms of
SCCA1 values. In a study investigating the importance of
SCCA1 in lung cancer and benign pulmonary diseases, it
was shown that SCCA1 may also be increased in benign
pulmonary diseases without squamous cell carcinoma
(<20 ng/mL), but it did not exceed 40 ng/mL in any of the
patients with benign lung cancer or squamous cell lung
cancer. It has been reported that SCCA1 is not affected by
age or sex but is associated with tumor progression and is
detected at the highest levels in metastatic patients [21].
The nonsignificant difference in SCCA1 values between
squamous cell carcinoma patients and PNET cases may be
due to the study containing a low number of squamous cell
lung cancer patients.
The present study has several limitations. First of all,
age and sex were statistically significantly different in
the 4 groups. The second limitation is that the number
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Figure 2. Multiple ROC analysis of ProGRP (progastrin-releasing peptide), NSE (neuron-specific enolase), and adjusted NSE
values, which are significant in distinguishing the healthy group from the pulmonary neuroendocrine tumor (PNET) group; P
> 0.05 for all values. AUC, Area under the curve; SE, standard error of the AUC; ProGRP, progastrin-releasing peptide; NSE,
neuron-specific enolase. Statistics using two-tailed Z-test.

of subgroup patient participants was low, especially in
the NSCLC group. The last limitation is that we did not
follow patients for mortality, so we have no data about
these markers and mortality in patients with PNET or
malignancy.
In conclusion, ProGRP can distinguish PNET patients
from NSCLC patients, and ProGRP with adjusted NSE
values can differentiate the PNET group from the benign
disease group. The ProGRP value is the only indicator that

distinguishes the PNET group from the other 3 groups.
After this study, our proposal for future studies is to
investigate the long-term effect of ProGRP on mortality in
PNET patients.
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